Joseph Galati

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

John G. McHutchison, Eric Lawitz, Mitchell L. Shiffman et al. · New England Journal of Medicine · 2009 · 1.2K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Paul Y. Kwo, Eric Lawitz, Jonathan McCone et al. · The Lancet · 2010 · 704 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database

Thomas A. Aloia, Bridget N. Fahy, Craig P. Fischer et al. · HPB · 2009 · 191 citations · Full text

Medicine, Perioperative Medicine, Surgery +11

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Mark Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie et al. · Gastroenterology · 2015 · 179 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study

Varun Saxena, Vandana Khungar, Elizabeth C. Verna et al. · Hepatology · 2017 · 162 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17